Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD). Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our locality. Statin no adherence, low uptake of adjuvant non-statin LLT, and therapeutic inertia are few potential causes for not achieving the LDL-C target. ESC recommends repeating blood test in 6-8 weeks after addition or alternation of LLT, but this recommendation was not routinely followed in current local practice due to resources constrain. This registry therefore aims to investigate the strategy of frequent monitoring of LDL-C and titration of LLT in achieving LDL-C treatment target at a dedicated specialist clinic.
Study Type
OBSERVATIONAL
Enrollment
1,000
Prince of Wales Hospital
Shatin, New Terrritories, Hong Kong
RECRUITINGLow-density lipoprotein cholesterol (LDL-C) level
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at baseline
Time frame: Baseline
Low-density lipoprotein cholesterol (LDL-C) level
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 8
Time frame: week 8
Low-density lipoprotein cholesterol (LDL-C) level
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 26
Time frame: Week 26
Low-density lipoprotein cholesterol (LDL-C) level
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 52
Time frame: Week 52
Low-density lipoprotein cholesterol (LDL-C) level
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at Baseline
Time frame: Baseline
Low-density lipoprotein cholesterol (LDL-C) level
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 8
Time frame: Week 8
Low-density lipoprotein cholesterol (LDL-C) level
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 26
Time frame: Week 26
Low-density lipoprotein cholesterol (LDL-C) level
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 52
Time frame: Week 52
Rate of subject meeting LDL-C target
Proportion of patients meeting prespecified LDL-C goals (\>50% reduction from baseline) at week 26.
Time frame: Week 26
Rate of subject meeting LDL-C target
Proportion of patients meeting prespecified LDL-C goals (\<1.4mmol/l) at week 26.
Time frame: Week 26
Rate of subject meeting LDL-C target
Proportion of patients meeting prespecified LDL-C goals (\<1.8mmol/L) at week 26.
Time frame: Week 26
12-Item Short Form Survey (SF-12)
Patient's quality of life as measured by SF-12 at baseline
Time frame: Baseline
12-Item Short Form Survey (SF-12)
Patient's quality of life as measured by SF-12 at week 8
Time frame: Week 8
12-Item Short Form Survey (SF-12)
Patient's quality of life as measured by SF-12 at week 26
Time frame: Week 26
12-Item Short Form Survey (SF-12)
Patient's quality of life as measured by SF-12 at week 52
Time frame: Week 52
Rate of major adverse cardiovascular event (MACE)
Occurrence of any major adverse cardiovascular event (MACE) at Baseline
Time frame: Baseline
Rate of major adverse cardiovascular event (MACE)
Occurrence of any major adverse cardiovascular event (MACE) at week 8
Time frame: Week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Rate of major adverse cardiovascular event (MACE)
Occurrence of any major adverse cardiovascular event (MACE) at week 26
Time frame: Week 26
Rate of major adverse cardiovascular event (MACE)
Occurrence of any major adverse cardiovascular event (MACE) at week 52
Time frame: Week52
Modification of lipid lowering therapy (LLT)
Modification of lipid lowering therapy (LLT) at week 8
Time frame: Week 8
Modification of lipid lowering therapy (LLT)
Modification of lipid lowering therapy (LLT) at week 26
Time frame: Week 26
Modification of lipid lowering therapy (LLT)
Modification of lipid lowering therapy (LLT) at week 52
Time frame: Week 52
Lipid Lowering Therapy adherence
LLT adherence, expressed in proportion of days covered, at week 52
Time frame: Week 52
Tolerability of Lipid Lowering Therapy
Rate of adverse drug event reported by subjects on lipid lowering therapy at week 52
Time frame: Week 52